Kodiak Sciences announced that its Phase III programs for Zenkuda (tarcocimab tedromer) met primary endpoints in wet age-related macular degeneration versus Regeneron’s Eylea, using individualized dosing intervals. The company said the approach enabled more than half of trial participants to extend treatment to once every six months compared with Eylea’s more frequent schedule. Shares surged on the readout, and Kodiak said it plans to seek FDA approval for Zenkuda in wet AMD alongside additional eye indications in the fourth quarter of 2026. The results mark a turnaround for a program that previously missed the mark and now leverages a patient-specific dosing strategy guided by ocular fluid status.